Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06022445
Other study ID # PKUPH-model validation
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2023
Est. completion date December 30, 2024

Study information

Verified date August 2023
Source Peking University People's Hospital
Contact Xiaohui Zhang, MD
Phone +86 13522338836
Email zhangxh@bjmu.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Validation of CARPET prognostic model for septic shock after allo-HSCT: a multicenter, prospective, and cohort study


Description:

A clinical prognostic model named CARPET model for septic shock after allo-HSCT has been developed and internally retrospectively validated. A multicenter, prospective cohort study is planned to validate this clinical prediction model again. The equation of the prediction model for 28-day mortality was as follows: Probability(28-day mortality)=(exp⁡(Y))/(1+exp⁡(Y)) where Y=2.343+1.328* Time of septic shock- 0.085* Albumin + 0.016 * Bilirubin-0.003*PaO2/FiO2 +0.127*Lactate- 0.011 * Glomerular filtration rate


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 200
Est. completion date December 30, 2024
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - age >18 years - underwent allo-HSCT - diagnosed with septic shock Exclusion Criteria: - experienced septic shock before enrollment - relapsed or progressed after HSCT

Study Design


Related Conditions & MeSH terms


Intervention

Other:
CARPET prognostic model
For patients diagnosed with septic shock, we obtained the information in CARPET prognostic model including time of septic shock, albumin, bilirubin, PaO2/FiO2, lactate, and GFR. We calculated the CARPET risk score and the 28-day mortality probability according to CARPET logistic regression model.

Locations

Country Name City State
China Peking University Insititute of Hematology, Peking University People's Hospital Beijing Beijing

Sponsors (11)

Lead Sponsor Collaborator
Peking University People's Hospital First Affiliated Hospital of Harbin Medical University, Guangzhou University of Chinese Medicine, Navy General Hospital, Beijing, Peking Union Medical College, People's Hospital of Xinjiang Uygur Autonomous Region, Second Hospital of Shanxi Medical University, Shanghai Zhongshan Hospital, Shanxi Dayi Hospital, The First Affiliated Hospital of Zhengzhou University, The Second Hospital of Hebei Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 28-day mortality Dead or alive at day 28 after septic shock diagnosis 28 days
Secondary ICU length of stay Days in the ICU after septic shock diagnosis up to 1 year
Secondary 90-day mortality Dead or alive at day 90 after septic shock diagnosis 90 days
Secondary Time on ventilator Days in need of mechanical ventilation up to 1 year
See also
  Status Clinical Trial Phase
Completed NCT03482154 - Malglycemia in the Pediatric Hematopoietic Stem Cell Transplant Population
Recruiting NCT06080490 - Tacrolimus Blood Concentration and Transplant-related Outcomes in Pediatric HSCT Recipients
Completed NCT03042676 - Electronic Database for the Follow up of the ATG_FamilyStudy
Recruiting NCT03871296 - DNA Methylation in Allogeneic Hematopoietic Stem Cell Transplantation.
Recruiting NCT04502628 - Hyperbaric Oxygen Therapy for Hemorrhagic Cystitis Post HSCT N/A
Recruiting NCT03793517 - Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT Phase 2/Phase 3
Completed NCT03454568 - The Patients' Experience After Stem Cell Transplant
Recruiting NCT05466201 - The Use of Eltrombopag Post HSCT in BMFS Phase 2/Phase 3
Not yet recruiting NCT04080622 - Evaluate the Efficacy of Selenium for the Prevention of Chemotherapy-induced Mucositis During Autologous Stem Cell Transplantation. Phase 3
Recruiting NCT05523336 - Pro-ADM vs PCT in Patients With Complications Post Hematopoietic Stem Cell Transplantation
Completed NCT03355235 - Brilliant Study: Assessing Cognition in Myeloma Patients Undergoing Transplant
Completed NCT04888286 - DSAs in Patients Undergoing Allo-HSCT From Mismatched Donors
Not yet recruiting NCT05421416 - Loratadine for the Prevention of G-CSF-related Bone Pain Phase 2
Recruiting NCT04167683 - Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
Active, not recruiting NCT03967665 - Risk Stratification-directed NAC for Prevention of Poor Hematopoietic Reconstitution Phase 3
Withdrawn NCT05104268 - Study of a New Medical Device for Oral Mucositis Early Phase 1
Recruiting NCT04623424 - Intestinal Microbiota in Stem Cell Transplant Transplant Admission
Active, not recruiting NCT04669210 - PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT Phase 2
Completed NCT03489551 - Feasibility of Prophylactic Haldol to Prevent Delirium in Cancer Patients Phase 4
Completed NCT04106089 - Sleep in Pediatric HSCT N/A